HALO · Halozyme Therapeutics, Inc.
Price
Snapshot
50 fields · last close| Market Cap | $14.79B |
| P/E | 35.30 |
| Float | 111.9M |
| Beta | 0.87 |
| Volatility 30D | 29.2% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 74.8 |
| Price | 125.43 |
| Change | −3.77% |
| Prev Close | 130.34 |
| Open | 130.81 |
| Day Low | 126.86 |
| Day High | 130.98 |
| Avg Vol | 2 |
| Avg $ Vol | $275.6M |
| 52W High | 134.00 |
| 52W Low | 61.23 |
| 52W Pos | 88.2% |
| From High | −6.40% |
| From Low | +104.85% |
| Max DD 1Y | −24.13% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +1.99% |
| SMA 50 | +9.13% |
| SMA 200 | +48.89% |
| RSI (14) | 72.8 |
| Vol 90D | 40.7% |
| Vol 1Y | 36.4% |
| 1Y Range | 61–134 |
| Daily bars | 549 |
| Perf Week | +0.24% |
| Perf Month | +18.79% |
| Perf Quarter | +51.98% |
| Perf Half Y | +96.44% |
| Perf Year | +96.89% |
| Perf YTD | +78.40% |
| Prev Day | −3.77% |
| Clavix | B |
| Debt / Eq | 43.89 |
| Curr Ratio | 4.66 |
| Int Cover | 39.7× |
| FCF Margin | 46.2% |
| Rev Growth | +37.5% |
| Profit | Profitable |
| Leverage | Very High |
| Sector rank | 15 / 35 |
Clavix risk grade
regraded every trading dayHALO grades B, 74.8 of 100. Steadiest on Macro Resilience (68), most exposed on Price Stability (56, mixed). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 15 of 35 in Biotechnology by Clavix score.
How rough the ride is
| HALO | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.87 | 0.49 |
| 30-day realized volatilityannualized, from daily closes | 29.2% | 46.0% |
| Max drawdown, past yearworst peak-to-trough fall | −24.1% | — |
| Typical daily movemedian absolute daily change | 1.22% | — |
| Days beyond ±3%of the last 252 sessions | 30 (12%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| HALO | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.87 | 0.49 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low 54% of 35 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| HALO | |
|---|---|
| 1 week | +0.2% |
| 1 month | +18.8% |
| Year to date | +78.4% |
| 1 year | +96.9% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| HALO | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 17 Sep |
| Average score0 most bearish, 100 most bullish | 68 |
| Bullish · bearisharticles above 60 · below 40 | 24 · 1 |
| Directionarticles whose tone is improving vs worsening | 24 ↑ 1 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 35 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| HALO | |
|---|---|
| Revenue growthyear over year | +37.5% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openThe article forecasts that Halozyme will beat third-quarter earnings estimates, driven by strong demand for drugs developed with partners. It says higher royalties, payments based on partner drug sales, should lift revenue.
Halozyme reported 47.70% revenue growth, a 173.67% return on the equity investors have in the company, and more than $337 million in free cash flow, meaning cash remaining after operating expenses and capital spending. Its stock traded at $125.63, the top of its 52-week range, while its forward earnings multiple was a relatively low 11.76.
MarketBeat reports that 13 research firms cover Halozyme Therapeutics, with a consensus recommendation of “Moderate Buy”; one analyst rates the stock a sell, and the provided text ends mid-sentence. The excerpt is too limited to establish any operational, financial, regulatory, or competitive development.
Halozyme’s shares are up 80% this year and have hit new highs, while the article describes the company as rivaling Merck. Halozyme develops technology that lets drugs given through intravenous infusions be administered as under-the-skin injections.
Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics earned top Zacks rankings, with cited growth drivers ranging from streaming advertising to drug demand. The article body provides no supporting figures or further details.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma, Inc. | B | $15.17B | — | 1.12 | Compare |
| ASND | Ascendis Pharma A/S | B+ | $16.09B | 18.70 | 0.38 | Compare |
| NBIX | Neurocrine Biosciences, Inc. | B+ | $16.81B | 23.46 | 0.32 | Compare |
| EXEL | Exelixis Inc | B+ | $17.75B | 19.85 | 0.40 | Compare |
| ALNY | Alnylam Pharmaceuticals, Inc. | C- | $21.57B | 7.86 | 0.45 | Compare |
| TGTX | TG Therapeutics, Inc. | B- | $9.43B | 21.06 | 1.77 | Compare |
| CAI | Caris Life Sciences, Inc. | C | $9.39B | 88.30 | 0.41 | Compare |
| PTGX | Protagonist Therapeutics, Inc. | B | $9.28B | 110.85 | 1.21 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.